Advertisement
"We're thrilled to have this unique partnership opportunity with BIO intheir tireless efforts to increase the relevant and timely dissemination ofsome of the most highly technical and challenging scientific issues of today,"said Alexander Saint-Amand, Chief Executive Officer of GLG. "Our company'slong-standing mission is to empower decision-makers by connecting them to theacademic and industry leaders driving innovation and productivity in ourglobal economy."
Advertisement
Through this partnership, BIO will tap into GLG's network of experts fromaround the world in order to identify the most relevant thought leaders todiscuss the latest issues and trends affecting drug development and clinicaldesign in the biotechnology industry.
"Gerson Lehrman Group is an ideal partner for BIO's annual investmentconferences with deep access to the clinical experts and investigators who canbring insights to pipeline research and current clinical practices," saidJames C. Greenwood, president and CEO of BIO. "Our Therapeutic Workshops andBusiness Roundtable discussions focus on educating investors and industrymanagement on the issues that face product innovation, capitalization andcommercialization."
The BIO CEO & Investor Conference is the largest independent biotechnologyinvestor conference focused on publicly-traded companies. The conferencefeatures issue-oriented plenary sessions, educational sessions on therapeuticareas and business issues, company presentations, one-on-one meetings, andnetworking opportunities.
To see the latest updates on 2008 programming and speakers for BIO CEO &Investor Conference, please visithttp://ceo.bio.org/opencms/ceo/2008/index.jsp.
About Gerson Lehrman Group
Gerson Lehrman Group (GLG) provides technology and services to support amarketplace for expertise. Since 1998, its platform for consultation andcollaboration has helped the world's leading financial services firms,consultancies, corporations, and nonprofits find, engage, and manage expertsin a broad range of industries and disciplines. GLG's unparalleled network ofthe world's leading expert consultants, known as the GLG Councils, includesmore than 175,000 subject-matter experts who educate and provide insight todecision-makers through a wide range of consulting methods, includingtelephone consultations, expert surveys and seminars. GLG has invested in oneof the world's most sophisticated infrastructures for expert recruiting andcompliance. For more information about GLG, please visit www.glgroup.com.
About BIO and the Tenth Annual BIO CEO & Investor Conference
Now in its tenth year, the BIO CEO & Investor Conference is the largestindependent biotechnology investor conference focused on publicly-tradedcompanies. The conference provides a neutral forum where institutionalinvestors, industry analysts, and senior biotechnology executives have theopportunity to shape the future investment landscape of the biotechnologyindustry. The conference features issue-oriented plenary sessions, educationalsessions focused on hot therapeutic areas and key business issues, companypresentations, one-on-one meetings, and networking opportunities. Theconference is hosted by the Biotechnology Industry Organization (BIO),representing more than 1,150 biotechnology companies, academic institutions,state biotechnology centers and related organizations across the United Statesand 31 other nations. BIO produces the BIO International Convention, theworld's largest gathering of the biotechnology industry.Contacts: Gerson Lehrman Group Margaret M. Molloy 212 880-6569 [email protected]
